This Research Topic aims to honour the 80th birthday of Professor Peter Illes, who is a member of the European Academy of Sciences, the founder/first president of the German Purine Club, and Honorary President of the Chinese Purine Club. He established a worldwide co-operation network on purinergic signalling and is an internationally recognized leader in the field. We aim to collect research articles and reviews from friends, colleagues and co-operation partners of Dr. Illes to showcase, build on and develop research being achieved related to the physiological/pathophysiological roles of purines in the central nervous system (CNS). Adenosine Triphosphate (ATP) is an intracellular energy-storing molecule, but may also reach the extracellular space, where it participates in cell-to-cell signalling. For this purpose, ATP utilises a range of purinergic receptors activated either by ATP itself (P2X receptors; seven subtypes) or by ATP/ADP and UTP/UDP (P2Y receptors; 8 subtypes) and finally via its enzymatic degradation product, adenosine (P1/A receptors; 4 subtypes). Purine nucleotides and nucleosides together with the whole plethora of receptors and degrading enzymes constitute the purinome. This fascinating and extensive network exists both in the animal kingdom and in humans and is essential in regulating important physiological functions. Disturbances in the network can lead to a variety of illnesses clinically associated with both neurological or psychiatric traits. In recent years, hope has arisen that pharmacological chemistry together with various newly developed methods, will enable researchers to discover and design efficient drugs for treating these neurodegenerative and affective diseases.

World-renowned coverage of today's pharmacology at your fingertips - Keeps you up-to-date with new information in this fast-changing field, including significantly revised coverage of CNS drugs, cognitive enhancers, anti-infectives, biologicals/biopharmaceuticals, lifestyle drugs, and more. - Includes access to unique features, including more than 100 brand new chapter-specific multiple-choice questions and 6 new cases for immediate self-assessment. - Features a color-coded layout for faster navigation and cross-referencing. - Clarifies complex concepts with Key Points boxes, Clinical Uses boxes and full-color illustrations throughout.

Rang and Dale's Pharmacology is internationally acknowledged as the core textbook for students of pharmacology, and has provided accessible, up-to-date information on drugs and their mechanism of action for more than 30 years. Now in its tenth edition, it has been updated to include important new drugs such as gene therapies, personalised medicines and the new wave of RNA drugs. However it has not lost any of the elements that have contributed to its popularity, such as color coding and illustrations, making it reader-friendly while comprehensively covering the depth of detail required. This essential book is recommended as the first-choice undergraduate text for science and medical students and junior doctors and will also be useful for students in other professional disciplines such as pharmacy, veterinary medicine and nursing. - Comprehensive information on drug mechanisms, basic physiology and biochemistry, and underlying pathophysiology of disease – suitable for students from many disciplines - Clear figures to aid understanding, including data figures as well as mechanistic diagrams, - Key points box summaries, clinical boxes and colour-coded chapters help to master difficult concepts - Emphasis on therapeutic drugs to help apply theory to practice - Over 150 questions and 12 clinical cases to test your knowledge - New chapters on drugs and the eye and the pharmacological management of headache - Revised information on biopharmaceuticals (including RNA drugs), antivirals (including Covid-19 therapies) as well as general principles of antimicrobial therapy. - A completely revised and updated chapter on lifestyle drugs - Recent advances in oxygen sensing and response to reduced oxygen tension - Expanded chapters on dementia and analgesic drugs

Frontiers in Pharmacology was launched in 2010, with a number of sections which were eventually reorganized. The founding Field Chief Editor was Prof. Théophile Godfraind, an eminent scientist active in cardiovascular pharmacology, who pioneered the discovery of calcium antagonists. At that time he invited me to serve as Chief Editor for a section named “Analytical and Experimental Pharmacology”. Later on, our section enlarged and was re-named as “Experimental Pharmacology and Drug Discovery” to outline the translational potential of fundamental pharmacological research and theoretical analysis to the improvement of human health, through the invention of novel medicinal products. We are now entering the 10th year of editorial activity, which sees the publication of the 1,000th paper in our section. Such an achievement is very rewarding for us and our community, but it is even more remarkable when placed into the timeline of our development. In fact, in a 10-year frame we have significantly grown in quantity and quality, e.g. both in number of published papers and in scientific impact. [From a personal perspective by Salvatore Salomone, Specialty Chief Editor]

The text ranges from drugs that affect the mood and behavior to hypnotics, narcotics, anticonvulsants, and analgesics, as well as a variety of drugs that affect the autonomic nervous system and psychoactive drugs used for non-medical reasons - nicotine, alcohol, opiates, psychostimulants and cannabis."--BOOK JACKET.

Presents current information on the molecular mechanisms of drug action. Provides 159 essays describing groups of drugs and drug targets. Several essays deal with general principles of pharmacology, such as drug tolerance, drug addiction, or drug metabolism.